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petition between brand-name and generic drugs was observed in
the US Medicaid marketplace.
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OBJECTIVE: In 2002, FDA added a boxed warning to the label-
ing of the antidepressant nefazodone describing its association
with acute liver failure and recommending liver function testing.
The aim of this study was to assess the impact of relabeling on
nefazodone utilization in community practice. METHODS: 
De-identiﬁed prescription claims from PharMetrics, a US medical
claims database vendor, were evaluated 45 months pre and 21-
months post relabeling for patients with ≥1 nefazodone claim
and ≥90 days enrollment history. The average number of unique
prescribers and total (TRx) and new-use (NRx) nefazodone pre-
scriptions were calculated by quarter and stratiﬁed by physician
specialty: primary care (PCP) (general practitioner, family prac-
titioner, internist) vs. psychiatry. New-use was deﬁned as the ﬁrst
nefazodone prescription. Changes in prescribing trends were
evaluated with t-tests (unequal variance). RESULTS: Relabeling
caused a pronounced reversal in TRx prescribing trends (p <
0.001). Prior to relabeling, TRx’s increased 5,676 Rx/quarter
(95% CI: 4592–6760) peaking at 30,688 (October–December,
2001). Immediately following relabeling, TRx’s dropped 28% 
to 21,994 (January–March, 2002) with a sustained decrease of
13, 582 TRx/quarter (95% CI: 8646–18,518) on average
through July–September, 2003. A similar signiﬁcant reversal was
also seen for NRx’s (p < 0.001). PCP prescribing was more 
sensitive to relabeling than psychiatrist prescribing with an
average reversal in prescribing trends of 7542 TRx’s /quarter
(95% CI: 7125–7959) for PCP’s compared to 336 TRx’s/quarter
(95% CI: 291–381). The number of unique nefazodone pre-
scribers also changed (p < 0.001) reversing from an average
increase of 1890/quarter (95% CI: 567–2213) prior to relabel-
ing to a decrease of 3209/quarter (95% CI: 1833–4585). CON-
CLUSION: The ﬁndings indicate added nefazodone safety
warnings had an immediate and sustained impact in decreasing
prescribing. While fewer patients appear at risk from nefazodone
liver toxicity following relabeling, further studies are needed to
determine whether liver enzyme monitoring practices also
changed.
PMH35
THE MAIN AND INTERACTION EFFECTS OF PATIENT AND
PHYSICIAN CHARACTERISTICS IN INFLUENCING THE
PRESCRIBING OF ANTIDEPRESSANTS
Tan H1, Lin SJ2, Lambert BL3, Sclove SL3
1HealthCore, Wilmington, DE, USA; 2University of Illinois, Chicago, IL,
USA; 3University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: The results of previous studies in examining
various factors inﬂuenced the prescribing of antidepressants have
not been entirely consistent. Some studies, for instance, showed
older patients were more likely to receive antidepressants, while
some showed the opposite. This study aimed to investigate how
patient and physician characteristics that might have inﬂuenced
the prescribing of antidepressants. METHODS: The 1997~2001
National Ambulatory Medical Care Survey (NAMCS) data was
analyzed with a popular data-mining tool–Exhaustive CHAID
classiﬁcation tree. The dependent variable was whether a patient
was prescribed an antidepressant. The candidate explanatory
variables were 13 characteristics associated with the patient or
the physician. From the candidate explanatory variables, the
CHAID algorithm will automatically check both the main and
interaction effects, and select the ones that can best differentiate
the groups with respect to the likelihood of prescribing an 
antidepressant. RESULTS: In total, 113,128 ofﬁce visits were
included. About 6.7% of them were prescribed at least 1 anti-
depressant between 1997 and 2000. Eleven signiﬁcant explana-
tory variables (diagnosis of depression, reporting depressive
symptoms, payment source, duration of visit, patient age, patient
gender, physician specialty, whether the physician was the patient
primary care physician (PCP), new/old patient, solo practice, the
location of the practice, and the region of the practice) and three
interaction effects (physician specialty and solo practice, patient
age and diagnosis of depression, and whether the physician was
the patient PCP and diagnosis of depression) were found by
CHAID. The results showed that for those who were diagnosed
with depression, younger patients were more likely to receive an
antidepressant. In contrast, for those without a diagnosis of
depression, older patients were more likely to receive antide-
pressants. CONCLUSIONS: These 11 explanatory variables
haven inﬂuenced the prescribing of antidepressants. The three
interaction effects detected by CHAID clariﬁed some of the
inconsistencies in the previous studies.
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OBJECTIVES: Beck Depression Index I and II (BDI) and Mood
and Anxiety Symptoms Questionnaire (MASQ) are well-known
instruments for clinical assessment of depression. Our objectives
were to compare measurement properties of BDI-I and II with
MASQ’s depression components and their measurement perfor-
mance with off-target samples. METHODS: Two samples of psy-
chologically healthy college students (sample size of 851 and 433
respectively) were randomly selected to complete BDI-I, MASQ
and BDI-II. Partial credit and rating scale model estimation with
WINSTEPS software were implemented for BDI-I/II and MASQ
respectively. Scale performance criteria included dimensionality,
rating scale functioning, separation and reliability, as well as con-
struct deﬁnition and convergence. RESULTS: All three instru-
ments demonstrated strong measurement properties, although
MASQ provided more coherent rating scale use, better person
and item separations and reliabilities, as well as slightly broader
measurement range. Residual principal components factor analy-
sis of MASQ found positively and negatively worded items
forming a structure that accounted for 15% of variance. This
factor is highly correlated with the measurement depression
dimension and does not present a threat to validity. CONCLU-
SIONS: Certain aspects of item performance in all instruments
should be improved. In particular, misﬁtting items could be
removed or revised and several redundant items dropped. It may
also be necessary to add items that ﬁll gaps left by scale reﬁne-
ment to maintain precision and reliability. There is a general need
to shorten the instruments for better and more efﬁcient depres-
sion measurement.
PMH37
A SYSTEMATIC REVIEW OF SUICIDALITY MEASURES IN
STUDIES USING SELECTIVE SEROTONIN REUPTAKE
INHIBITORS (SSRIS) IN CHILDREN AND ADOLESCENTS WITH
MAJOR DEPRESSIVE DISORDER (MDD)
Pfalzgraf AR, Kavookjian J, Scott V
West Virginia University, Morgantown, WV, USA
